[PDF] dermatologie cours et images
[PDF] lesion elementaire en dermatologie pdf
[PDF] livre de dermatologie pdf
[PDF] atlas dermatologie pdf
[PDF] cours dermatologie ppt
[PDF] affections dermatologiques courantes
[PDF] guide pratique de dermatologie pdf
[PDF] bouvard et pécuchet résumé détaillé
[PDF] bouvard et pécuchet lecture analytique
[PDF] bouvard et pécuchet chapitre 1 commentaire
[PDF] flaubert bouvard et pécuchet
[PDF] bouvard et pécuchet incipit analyse
[PDF] bouvard et pécuchet commentaire composé
[PDF] bouvard et pécuchet pdf
Sclérodermie systémique:
introduction, quels examens réaliserLuc Mouthon
Internal Medicine department,
Hôpital Cochin, Paris, France
& French National Reference Center for Systemic SclerosisInserm U1016, Institut Cochin
Consultant: Actelion, CSL Behring,
Cytheris, GSK, LFB Biotechnologies, Lilly,
Pfizer
Financial support to ARMIIC
Investigator: Actelion, CSL Behring, Pfizer
Financial support (grants): Actelion, CSL
Behring, GSK, LFB Biotechnologies, Pfizer
Conflictsof interest
SCLSCL
ÉÉRODERMIE SYSTRODERMIE SYST
ÉÉMIQUEMIQUE
Fibrose
PeauPoumonAppareil digestifCoeur
Hyperréactivité
vasculaireSyndrome de Raynaud
Crise Rénale
Hypertension artérielle
pulmonaireAutoimmunité
Autoanticorps
Anti-Scl70
Anti-centromère
Anti-ARNPolIII
vascular hyperreactivityIL-6, IL-8
PDGF TGF- bbbb CTGF gelatinase MCP-1 histamine, tryptase, IL-4, AFA stem cell factor, MCP-1 TGF- bbbb EI Q BT /R22 18 Tf0 1.00055 -1 -0 318.6 485.391 Tm
[(AECA microchimerism extracellular matrix protein synthesis environment geneticEndothelin-1
Prostacyclin
Nitric oxide
Tamby MC et al, Autoimmunity Rev, 2003
Systemic sclerosis: lesions at different stages
Gabrielli A. NEJM2009
Prévalence
158Sources multiplesSeine Saint DenisLe Guern126Source hôpitalDanemarkAsboe-Hansen31Sources multiplesWest midlandSilmanEurope21-53Santé publiqueTokyoTamaki7Santé publiqueJaponShinkaiAsie233Sources multiplesAustralie du sudRoberts-Thomson147-208Australie du sudChandranOcéanie190-750PopulationCaroline du sud
Maricq
242Sources multiplesDetroit
Mayes138HôpitalRochester
Michet
Etats Unis
Prévalence
/million techniqueRégionsAuteursCritères diagnostiques de
sclérodermie systémiqueArthritis Rheum, 1980
Critère majeurSclérose cutanée proximale
Critères mineursSclérodactylieCicatrices digitales, pertes de substanceFibrose pulmonaire des basesSclérodermie systémique si un critère majeur ou deux
critères mineursCriteresde classification des
formes débutantes de SSc Sclérodermie systémique limitéePhénomène de Raynaud +Soit anomalie capillaroscopiqueSoit Ac spécifique de la Sclérodermie systémique (anti-centromere, anti-topoisomérase 1, anti-fibrillarine, anti-PMScl, anti-fibrilline, anti-RNA pol I ou III àun titre1/100)Sclérodermie systémique cutanée limitéeEn plus des critères précédents, infiltration distale, en
aval des coudes et des genouxLeroy & Medsger, Rheumatology, 2001
Specific microvascular changes that characterize the different nailfold videocapillaroscopic SSc patternsHerrick A & Cutolo M A&R 2010
Clinical classification of SSc
Diffuse cutaneous SSc• Skin sclerosis proximal to elbows and knees • Inflammatory featuresprominent in 1st 3 years • Anti-Scl-70 or anti-RNApolymerase• Increased frequency of interstitial lung disease, renalcrisis, bowel & cardiacinvolvementScleroderma sine Scleroderma• No skin sclerosis
Limited cutaneous SSc• No skin sclerosis proximal to elbows and knees • Anti-centromere antibody(ACA) • CREST subgroup• Lung fibrosis, renal crisis & cardiac involvement lesscommon than in dcSScOverlap syndrome• Features include those of lcSSc or dcSSc with those of other autoimmune disease(s)
Poormoghim H,et al. Arthritis Rheum 2000; 43:444-51, Denton CP and Black CM, Trends Immunol2005; 26:596-602.Skin scoreVisceral involvement
SYSTEMIC SCLEROSIS : EVOLUTION
Diffuse
Limited cutaneous
0102 4
6 8Raynaud"s syndromeKidneyILD + PAH
Myositis
Bowell
ILD PAHBowell
0 10 2 4 6 8 Years Lung FaceUpper arm
Anterior
chestForearm
HandFingers
Thigh LegFootUpper arm
Abdomen
Forearm
HandFingers
Thigh Leg FootUninvolvedMild thickeningModerate thickeningSevere thickening 0 1 2 3The modified Rodnanskin
score (MRSS)Disease duration at peak skin score of
the patients who had dcSSc from theRoyal Free Hospital scleroderma
database. Nihtyanova SI, Denton CP. Rheum Dis Clin N Am 34 (2008) 161-179Shand L, et al. Arthritis Rheum2007; 56:2422-31.
Disease durationand skinscore in dcSSc
Change in skin score over 3 years in
the subgroupsSurvival in the subgroupsHigh baseline/improversDisease duration
12 24 361020304050
Low baseline/improversHigh baseline/non-improvers
mRSSHigh baseline/
improvers, n = 40Low baseline/improvers, n = 6725218010836020406080100
p=0.003High baseline/
non-improvers, n = 24Cumulative survival
Disease duration
Total Missing data lcSSc dcSSc
Number of patients, n(%) 1483 (100) 0 (0) 674 (45.5) 484 (32.7)Percentage of organ involvement by SSc subsets
RP94.4 0.1 96.3 94.2
Skin involvement 87.8 0.3 91.5 97.6
PAH 15.8 0.1 14.9 18.5
Pulmonary fibrosis 34.5 0.1 20.8 56.1Oesophagus 60 0.1 59.2 69.3Stomach 14.2 0.2 15.3 15.6Intestine 5.7 0.2 6.1 5.3Kidney 10.5 0.2 9.1 15.9Heart 14.6 0.2 12 23Musculoskeletal system 47.5 1.4 44.9 56.6Nervous system 6.4 2.2 4.1 7.1Sicca-symptoms 39.5 2.5 43.5 39.7Masticatory organ 24.1 7.2 23.7 34.1Prevalenceof visceral involvement in SSc
Hunzelmann N, et al. Rheumatology 2008; 47:1185-92.